Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$17.19
▲ $0.03 (+0.2%)
Market data updated: 09/19 01:06 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$91.29M
Day Range
$16.92 - $17.20
52-Week Range
$3.67 - $17.57
Beta
—
Next Earnings
—
Support
$15.66
Resistance
$17.35
RLYB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+258.7% (1Y)
Strengths: 17/26 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 34.9%
Growth
Biggest negative driver
Operating margin
Operating margin: -3853.6% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
64
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
74
Quality
58
Value
50
Momentum
92
Risk
48
Sentiment
86
Fundamental
30
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of RallyBio Corporation has centered on its strategic expansion through a merger with Avenzo Therapeutics, announced in early June 2026, aiming to accelerate next-generation oncology therapies. The deal includes a $215 million private placement, and investors have reacted positively, pushing RallyBio’s stock to a two-year high. While unrelated to RallyBio, headlines also mention its partners—VERAXA Biotech and Prolium Bioscience—advancing R&D and clinical programs in unrelated therapeutic areas.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Rallybio Corporation. News trend score: 86. Reason: 6 of the last 7 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
43
🎯 Conviction (vs. Emotion)
56
Psychology
81
Fundamentals
30
Technical
92
Valuation
50
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+8%
Market Narrative
62
Fundamental Reality
56
Narrative Gap
+6
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a **narrative-reality alignment** (gap: 0) but a **dominant herding dynamic**—traders appear to be reacting to peer performance rather than intrinsic signals. The **euphoria score (26)** hints at lingering optimism, possibly anchored by the stock’s 17.6% outperformance over 200 days, while **anchoring (11)** may keep traders near resistance. The absence of panic or overconfidence signals a cautious, peer-driven environment. The key question: *Will relative underperformance today trigger further herding or corrective buying?*
Updated: 09/09/2026, 03:29 AM
What could change this?
👥 What the crowd believes
""Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies""
""RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo""
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 11/100
🗣️ Why do they disagree?
The methodologies diverge sharply on RLYB, with the highest-scoring approaches—Walter Bagehot’s liquidity focus (100) and Peter Lynch’s growth potential (93)—seeing it as a resilient or undervalued opportunity, while the lowest-ranked, like Howard Marks’ late-cycle caution (35) and the efficient-market skeptics (53), treat it as either overpriced or unworthy of active selection. Defensive value investors like Benjamin Graham (82) and cycle analysts (Samuel Nelson, 85) find it attractive due to its fundamentals or technical positioning, but Fisher (65) and Smith (63) downgrade it for lacking exceptional quality or long-term clarity. Meanwhile, crowd psychology (Mackay, 62) and trend-following (Livermore, 57) flag red flags, while Marks’ mixed verdict (42) suggests the business may already reflect market optimism. The split reflects a tension between growth potential, defensive value, and skepticism about timing or valuation.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 93
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 81
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 74
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 65
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 65
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 61
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 57
Some discount, but not the deep 'net-net' bargain Graham's enterprising bar sets
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 50
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 45
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 33
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 32
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 24
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 14
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 11
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (11 bullish · 1 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-3853.6%
Net Margin
-1046.4%
EBITDA Margin
-3842.9%
ROE
-15.5%
ROA
-14.4%
ROIC
—
EPS
-$1.59
Cash
$31.37M
Total Debt
—
Current Ratio
14.50
Debt/Equity
—
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$10.30
Tangible Book Value per Share (Tangible NAV)
$10.30
Sentiment based on basic keywords (not AI) — 6 positive, 1 neutral, 0 negative out of the last 7 articles.
Benzinga · 9.9.2026
Exec Edge · 24.6.2026
Exec Edge · 22.6.2026
Stocktwits · 1.6.2026
BioPharma Dive · 1.6.2026
MT Newswires · 1.6.2026
Business Wire · 1.6.2026
Rallybio Corporation (RLYB) currently has a StockIQ AI score of 64/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
RLYB currently scores 64/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
RLYB's technical score is 92/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 34.9%; Earnings per share (EPS) growth: 85.0%; Net income growth: 84.5%.
Based on the real signals StockIQ computed: Operating margin: -3853.6% (negative); Net margin: -1046.4% (negative); Calmar: -0.25 (3y annualized return -23.3% / max drawdown 94.9%).
StockIQ has no recorded dividend payment history for RLYB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 21 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Boudreau Helen M | Exercise of Derivative Securities | 6.7.2026 | 3,562 | +3,562 | $2.38 |
| Boudreau Helen M | Exercise of Derivative Securities | 6.7.2026 | 3,562 | -3,562 | — |
| Boudreau Helen M | Exercise of Derivative Securities | 6.7.2026 | 6,542 | +3,562 | $2.38 |
| Boudreau Helen M | Exercise of Derivative Securities | 6.7.2026 | 0 | -3,562 | — |
| ADAR1 Capital Management, LLC | Open Market Purchase | 19.5.2026 | 200 | +200 | $13.80 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 19.5.2026 | 10,000 | +10,000 | $13.98 |
| Schneeberger Daniel | Open Market Purchase | 19.5.2026 | 926,152 | +10,000 | $13.98 |
| Schneeberger Daniel | Open Market Purchase | 19.5.2026 | 926,352 | +200 | $13.80 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 18.5.2026 | 6,009 | +6,009 | $13.98 |
| Schneeberger Daniel | Open Market Purchase | 18.5.2026 | 916,152 | +6,009 | $13.98 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 15.5.2026 | 200 | +200 | $13.95 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 15.5.2026 | 100 | +100 | $13.80 |
| Schneeberger Daniel | Open Market Purchase | 15.5.2026 | 909,943 | +100 | $13.80 |
| Schneeberger Daniel | Open Market Purchase | 15.5.2026 | 910,143 | +200 | $13.95 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 13.5.2026 | 4,081 | +4,081 | $13.80 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 13.5.2026 | 75,178 | +75,178 | $14.00 |
| Schneeberger Daniel | Open Market Purchase | 13.5.2026 | 834,665 | +4,081 | $13.80 |
| Schneeberger Daniel | Open Market Purchase | 13.5.2026 | 909,843 | +75,178 | $14.00 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 12.5.2026 | 800 | +800 | $13.83 |
| Schneeberger Daniel | Open Market Purchase | 12.5.2026 | 830,584 | +800 | $13.83 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 11.5.2026 | 25,000 | +25,000 | $14.00 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 11.5.2026 | 5,100 | +5,100 | $14.00 |
| ADAR1 Capital Management, LLC | Open Market Purchase | 11.5.2026 | 19,900 | +19,900 | $14.00 |
| Schneeberger Daniel | Open Market Purchase | 11.5.2026 | 784,884 | +5,100 | $14.00 |
| Schneeberger Daniel | Open Market Purchase | 11.5.2026 | 809,884 | +25,000 | $14.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
54,943 shares short as of 2026-08-31 · vs. 63,485 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
41.0% of trading volume this week was short selling, vs. 25.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology